Press Release Details

Cerus to Present at Two Upcoming Conferences

10/31/2017

CONCORD, Calif.--(BUSINESS WIRE)-- Cerus Corporation (NASDAQ:CERS) announced today that management will present at two upcoming investor conferences:

  • Stephens Fall Investor Conference at the Lotte New York Palace Hotel in New York City on November 7, 2017 at 2:00 PM ET. Kevin D. Green, vice president, finance and chief financial officer, will present for Cerus.
  • Canaccord Genuity Medical Technologies & Diagnostics Forum at the Westin Grand Central in New York City on November 9, 2017 at 2:30 PM ET. Dr. Laurence M. Corash, co-founder and chief scientific officer, will present for Cerus.

A live webcast of the presentations will be available on the Investor Relations page of the Cerus web site at http://www.cerus.com/ir. A replay will be available for approximately two weeks following the completion of the event.

ABOUT CERUS

Cerus Corporation is a biomedical products company focused in the field of blood transfusion safety. The INTERCEPT Blood System is designed to reduce the risk of transfusion-transmitted infections by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action of the INTERCEPT treatment is designed to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, as well as emerging pathogens such as chikungunya, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in the United States, Europe, the Commonwealth of Independent States, the Middle East and selected countries in other regions around the world. The INTERCEPT Red Blood Cell system is in clinical development. See http://www.cerus.com for information about Cerus.

INTERCEPT and the INTERCEPT Blood System are trademarks of Cerus Corporation.

Source: Cerus Corporation

Cerus Corporation

Tim Lee, 925-288-6137

Investor Relations Director

  • Global Headquarters

  • 2550 Stanwell Drive
    Concord, CA US 94520
    +1 925.288.6000
  • European Headquarters

  • Stationsstraat 79-D
    3811 MH Amersfoort, Netherlands
    +31 (0) 33 49 60 600